For over two decades, Rituximab and CHOP combination treatment (rCHOP) has remained
the standard treatment approach for diffuse large B-cell lymphoma (DLBCL). Despite …

Diffuse large cell B cell lymphoma (DLBCL) accounts for approximately 30%–40% of all non-
Hodgkin lymphoma (NHL) cases. Current first line DLBCL treatment results in long-term …

Diffuse large B cell lymphoma (DLBCL), the most common subtype of Non-Hodgkin
lymphoma, exhibits pathologic heterogeneity and a dynamic immunogenic tumor …

Interactions between stromal and lymphoma cells in the bone marrow are closely related to
drug resistance and therapy failure. Physiologically relevant pre-clinical three-dimensional …

Purpose B-cell non-Hodgkin lymphomas (B-NHLs) are the most common
lymphoproliferative malignancy. Despite targeted therapies, the bone marrow involvement …

Immunotherapies present a promising and rapidly growing field of treatment options for
cancer and other diseases. Most treatments developed by academic and industrial labs …

Follicular lymphomas (FLs) account for 35–40% of all adult lymphomas. Treatment typically
involves chemotherapy combined with the anti-CD20 monoclonal antibody (MAb) rituximab …

Introduction: The lymphoma microenvironment is increasingly recognized as crucial to
sustaining lymphoma cell growth and an important contributor to treatment outcome …

Background Diffuse large B-cell lymphoma (DLBCL) is a malignant tumour. Although some
standard therapies have been established to improve the cure rate, they remain ineffective …

Non-Hodgkin B-cell lymphomas (B-NHL) mainly develop within lymph nodes as aggregates
of tumor cells densely packed with their surrounding microenvironment, creating a tumor …